• Loading stock data…

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September

Last Updated on September 7, 2022 by GlobeNewsWire

NEW YORK and VIENNA, Sept. 07, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the following upcoming investor conferences:

Morgan Stanley Global Healthcare Conference, September 12-14, New YorkFireside Chat: September 13, 12:55pm ETH.C. Wainwright Global Investment Conference, September 12-14, New York

The Morgan Stanley Fireside Chat webcast will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. Archived replays will be accessible for 30 days following each event.

About HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media InvestorsMichael SzumeraMatt Beck Executive Director – CommunicationsExecutive Director – Investor Relationsmichael.szumera@hookipapharma.com matthew.beck@hookipapharma.com +1 917 561 8905 +1 917 209 6886

Print Friendly, PDF & Email
Spread the word

Reader Interactions

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: